From the perspective of the clinical care of T2D patients who require intensified injection therapy, our findings are consistent with existing treatment guidelines [1, 3] and a real-world study [47], showing that using a GLP-1RA versus insulin therapy has therapeutic benefits in terms of reduced risks of hypoglycemia and all-cause death. Here, INS is linked to type 2 diabetes mellitus.